Article Details

Cost Effectiveness Varies in TAS-102 Plus Bevacizumab Third Line Treatment

Retrieved on: 2024-10-10 21:40:36

Tags for this article:

Click the tags to see associated articles and topics

Cost Effectiveness Varies in TAS-102 Plus Bevacizumab Third Line Treatment. View article details on hiswai:

Excerpt

Patients with refractory metastatic colorectal cancer could use trifluridine/tipiracil (TAS-102) plus bevacizumab as a cost effective third line ...

Article found on: www.ajmc.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo